MDMA PTSD Experiment Concludes in Switzerland

[Enigma]

Got an email today from The Multidisciplinary Association for Psychedelic Studies today,

    

Dear MAPS Members and Friends,

I am excited to share with you that on Friday, January 8, 2010, the final experimental session took place in our Swiss study of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD). The twelfth and final subject received MDMA in the Stage 2 open-label portion of the trial, which means that he had previously been randomized to receive three experimental sessions with the low-dose placebo.  The final data point in this study will be two months from this last session. One year from now will be the final data point in the long-term follow-up study of these 12 subjects.

We are pleased to report that just like our U.S. MDMA/PTSD pilot study, there was an excellent safety record.  There was no evidence of harm caused to any of the subjects by administering research grade MDMA in a therapeutic setting. This fact alone is noteworthy when put in contrast with all of the exaggerated risk estimates over the past 25+ years claiming serious brain damage from a single dose of MDMA. Even more noteworthy for the future of prescription MDMA-assisted psychotherapy is that preliminary data analysis suggests statistically significant results in reduction of PTSD symptoms.
We at MAPS want to thank you for your support in funding this project. It has been over three years and over $225,000 since this study was officially initiated on October 19, 2006. It will be a few more years before we complete all of our Phase 2 studies, leading to an End-of-Phase 2 meeting with the FDA to plan our Phase 3 studies, which will take another 3-5 years to complete. Through patience, diligence, rigorous scientific methodology, exceptional therapists and courageous patients, we can transform MDMA into a prescription medicine approved by the U.S. FDA and the European Medicines Agency. We are grateful that we can count on your support through this process!



Sincerely,

Randolph Hencken, M.A.
Director of Communication and Marketing, MAPS
Conference Organizer

I have high hopes for this study.  In this day and age, the therapeutic use of MDMA could greatly improve the quality of life for veterans, victims of terrorism, and survivors of natural disasters, and any other victims of PTSD.   

[voodoo scientist]

This is extremely exciting (their website is here). I believe MDMA has significant therapeutic properties in treating PTSD, depression and anxiety disorders, as well as others, in combination with counseling.

[pert -5]

This is extremely exciting (their website is here). I believe MDMA has significant therapeutic properties in treating PTSD, depression and anxiety disorders, as well as others, in combination with counseling.

I agree.  A lot of banned chemical reagents have so much potential in regards to the amelioration of the mental state of so many people.  I blame the government!!!!